XM tillhandahåller inte tjänster till personer bosatta i USA.
E
E

EMS


Nyheter

Swiss EMS Chemie H1 sales drop 8.1%, cuts 2024 sales guidance

UPDATE 1-Swiss EMS Chemie H1 sales drop 8.1%, cuts 2024 sales guidance Adds analyst comments in paragraphs 3, 8, 10, share move in paragraph 2 July 12 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S cut its 2024 sales guidance on Friday after reporting weaker-than-expected first-half sales, citing currency effects as the Swiss franc strengthened.
E
G
K

EMS Chemie slumps on H1 sales miss

BUZZ-EMS Chemie slumps on H1 sales miss ** Shares of Swiss nylon manufacturer EMS Chemie EMSN.S fall around 7% to more than two-month lows after its H1 sales missed expectations ** Net sales in the first half of the year declined 8.1% to 1.09 billion Swiss francs ($1.22 billion) ** "1H24 sales were weak and did not meet expectations," Vontobel says
E

Swiss EMS Chemie cuts 2024 sales guidance on currency effects

Swiss EMS Chemie cuts 2024 sales guidance on currency effects July 12 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S cut its 2024 sales guidance on Friday, citing currency effects as the Swiss franc strengthened. The company said it expects its 2024 net sales to fall slightly, after previously forecasting net sales in line with the 2023 figure of 2.19 billion Swiss francs ($2.44 billion).
C
E
G

Swiss stocks - Factors to watch on July 12

Swiss stocks - Factors to watch on July 12 July 12 - Here are some of the main factors that may affect Swiss stocks on Friday: EMS CHEMIE HOLDING AG EMSN.S Reports H1 EBITDA up at 318 million Swiss francs. PARTNERS GROUP HOLDING AG PGHN.S Reports 11 billion dollars in H1 client demand, reconfirms FY fundraising guidance. ANALYSTS' VIEWS DOCMORRIS DOCM.S - HSBC CUTS TARGET PRICE TO CHF 75 FROM CHF 115 ECONOMY No major Swiss economic data scheduled.
E

EMS Chemie H1 EBITDA up at CHF 318 Million

BRIEF-EMS Chemie H1 EBITDA up at CHF 318 Million July 12 (Reuters) - EMS Chemie EMSN.S : H1 NET SALES AMOUNTING TO CHF 1,087 MILLION (1,183) H1 NET OPERATING INCOME OF CHF 291 MILLION (280) H1 EBITDA of CHF 318 million (305) FOR 2024, EMS EXPECTS NET SALES SLIGHTLY BELOW PREVIOUS YEAR DUE TO CURRENCY EFFECTS AND CONTINUES TO EXPECT NET OPERATING IN
E

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead July 5 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 08-Jul-2024 NTS INDUa.ST Industrivarden AB Q2 2024 Industrivarden AB Earnings Release 08-Jul-2024 05:30 WIHL.ST Wihlborgs Fastigheter AB Q2 2024 Wihlborgs Fastigheter AB Earnings Release 09-Jul-2024 06:00 KINVb.ST Kinnevik AB Q2 2024 Kinnevik AB Earnings Release 10-J
E
E
G
I
K
S

Arkema, Fuller Smith & Turner, Siemens Energy

EUROPE RESEARCH ROUNDUP- Arkema, Fuller Smith & Turner, Siemens Energy May 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Fuller Smith & Turner and Siemens Energy, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 117 from EUR 107 * Bytes Technology Group Plc BYIT.L : Deutsche Bank initiates coverage with buy rating * Fuller Smith & Turner Plc FSTA.L : Deutsche Bank initiates coverage with buy
A
A
A
A
B
B
B
B
C
E
E
G
A
A
B
D
G

Swiss EMS Chemie's sales slip on depressed demand and higher costs

UPDATE 1-Swiss EMS Chemie's sales slip on depressed demand and higher costs Adds currency impact in paragraph 2, analyst comments in 3 April 25 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S reported an 11% drop in first-quarter net sales on depressed consumer demand and lingering high raw material and freight costs, it said on Thursday, while confirming its 2024 forecast.
E

Swiss EMS Chemie posts 11% drop in Q1 sales on stronger Swiss franc

Swiss EMS Chemie posts 11% drop in Q1 sales on stronger Swiss franc April 25 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S reported a double-digit drop in first-quarter net sales as the Swiss franc's strengthening curtailed net sales development, it said on Thursday, while confirming its 2024 forecast. The Group's Q1 net sales decreased 11.3% year-on-year to 545 million Swiss Franc ($596.21 million), in line with two analysts' predictions that had projected a yearly drop in the range of
C
E

Swiss stocks - Factors to watch on April 25

Swiss stocks - Factors to watch on April 25 ZURICH/BERLIN, April 25 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: UBS UBSG.S A new lawsuit by U.S. hedge fund Appaloosa LP accuses the former Credit Suisse of misleading investors about its health before $17 billion of its bonds were written down to zero in a government-orchestrated rescue by Swiss rival UBS UBSG.S.
A
C
E
N
T
U
W
T

Ems Chemie Sees 2024 EBIT Slightly Above Previous Year

BRIEF-Ems Chemie Sees 2024 EBIT Slightly Above Previous Year April 25 (Reuters) - Ems Chemie Holding AG EMSN.S : FOR THE BUSINESS YEAR 2024, EMS EXPECTS THE ECONOMIC ENVIRONMENT TO REMAIN CHALLENGING OUTLOOK: FOR 2024, EMS CONTINUES TO EXPECT NET SALES AT PREVIOUS YEAR'S LEVEL AND NET OPERATING INCOME (EBIT) SLIGHTLY ABOVE PREVIOUS YEAR ACHIEVED NE
E



Villkor

Populära tillgångar

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.